Brooke was only three years old when she first learned about desmoid tumors. “My mother had six or seven,” she recalls.

In a report released yesterday, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Springworks Therapeutics (SWTX ...

Piper Sandler lowered the firm’s price target on Immunome (IMNM) to $21 from $23 and keeps an Overweight rating on the shares after the ...

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from ...

An analysis of SpringWorks Therapeutics, Inc., including recent FDA approval, promising sales, and future funding for ...

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their ...

SpringWorks to present long-term efficacy and safety data from phase 3 DeFi trial of Ogsiveo in adults with desmoid tumours at CTOS 2024 meeting ...

In November 2023, the FDA approved SpringWorks’ oral gamma-secretase inhibitor, Ogsiveo (nirogacestat), for treating adult patients with progressing desmoid tumors who require systemic treatment.

SpringWorks Therapeutics’ SWTX oral gamma-secretase inhibitor, Ogsiveo (nirogacestat), was approved by the FDA for treating adult patients with progressing desmoid tumors in November 2023.

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highli ...